The cost-effectiveness of rotavirus vaccination in Malawi

Stephen Berry, Benjamin Johns, Chuck Shih, Andrea A. Berry, Damian G. Walker

Research output: Contribution to journalArticle

Abstract

Background. Rotarix (GlaxoSmithKline), a newly licensed rotavirus vaccine requiring 2 doses, may have the potential to save hundreds of thousands of lives in Africa. Nations such as Malawi, where Rotarix is currently under phase III investigation, may nevertheless face difficult economic choices in considering vaccine adoption. Methods. The cost-effectiveness of implementing a Rotarix vaccine program in Malawi was estimated using published estimates of rotavirus burden, vaccine efficacy, and health care utilization and costs. Results. With 49.5% vaccine efficacy, a Rotarix program could avert 2582 deaths annually.With GAVI Alliance cofinancing, adoption of Rotarix would be associated with a cost of $5.07 per disability-adjusted life-year averted.With market pricing, Rotarix would be associated with a base case cost of $74.73 per disability-adjusted life-year averted. Key variables influencing results were vaccine efficacy, under-2 rotavirus mortality, and program cost of administering each dose. Conclusions. Adopting Rotarix would likely be highly cost-effective for Malawi, particularly with GAVI support. This finding holds true across uncertainty ranges for key variables, including efficacy, for which data are becoming available.

Original languageEnglish (US)
JournalJournal of Infectious Diseases
Volume202
Issue numberSUPPL. 1
DOIs
StatePublished - Sep 1 2010

Fingerprint

Malawi
Rotavirus
Cost-Benefit Analysis
Vaccination
Costs and Cost Analysis
Vaccines
Rotavirus Vaccines
Quality-Adjusted Life Years
Patient Acceptance of Health Care
RIX4414 vaccine
Health Care Costs
Uncertainty
Economics
Mortality

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

The cost-effectiveness of rotavirus vaccination in Malawi. / Berry, Stephen; Johns, Benjamin; Shih, Chuck; Berry, Andrea A.; Walker, Damian G.

In: Journal of Infectious Diseases, Vol. 202, No. SUPPL. 1, 01.09.2010.

Research output: Contribution to journalArticle

Berry, Stephen ; Johns, Benjamin ; Shih, Chuck ; Berry, Andrea A. ; Walker, Damian G. / The cost-effectiveness of rotavirus vaccination in Malawi. In: Journal of Infectious Diseases. 2010 ; Vol. 202, No. SUPPL. 1.
@article{8c68321fb1db481a8a43374f82a2f329,
title = "The cost-effectiveness of rotavirus vaccination in Malawi",
abstract = "Background. Rotarix (GlaxoSmithKline), a newly licensed rotavirus vaccine requiring 2 doses, may have the potential to save hundreds of thousands of lives in Africa. Nations such as Malawi, where Rotarix is currently under phase III investigation, may nevertheless face difficult economic choices in considering vaccine adoption. Methods. The cost-effectiveness of implementing a Rotarix vaccine program in Malawi was estimated using published estimates of rotavirus burden, vaccine efficacy, and health care utilization and costs. Results. With 49.5{\%} vaccine efficacy, a Rotarix program could avert 2582 deaths annually.With GAVI Alliance cofinancing, adoption of Rotarix would be associated with a cost of $5.07 per disability-adjusted life-year averted.With market pricing, Rotarix would be associated with a base case cost of $74.73 per disability-adjusted life-year averted. Key variables influencing results were vaccine efficacy, under-2 rotavirus mortality, and program cost of administering each dose. Conclusions. Adopting Rotarix would likely be highly cost-effective for Malawi, particularly with GAVI support. This finding holds true across uncertainty ranges for key variables, including efficacy, for which data are becoming available.",
author = "Stephen Berry and Benjamin Johns and Chuck Shih and Berry, {Andrea A.} and Walker, {Damian G.}",
year = "2010",
month = "9",
day = "1",
doi = "10.1086/653578",
language = "English (US)",
volume = "202",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "SUPPL. 1",

}

TY - JOUR

T1 - The cost-effectiveness of rotavirus vaccination in Malawi

AU - Berry, Stephen

AU - Johns, Benjamin

AU - Shih, Chuck

AU - Berry, Andrea A.

AU - Walker, Damian G.

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Background. Rotarix (GlaxoSmithKline), a newly licensed rotavirus vaccine requiring 2 doses, may have the potential to save hundreds of thousands of lives in Africa. Nations such as Malawi, where Rotarix is currently under phase III investigation, may nevertheless face difficult economic choices in considering vaccine adoption. Methods. The cost-effectiveness of implementing a Rotarix vaccine program in Malawi was estimated using published estimates of rotavirus burden, vaccine efficacy, and health care utilization and costs. Results. With 49.5% vaccine efficacy, a Rotarix program could avert 2582 deaths annually.With GAVI Alliance cofinancing, adoption of Rotarix would be associated with a cost of $5.07 per disability-adjusted life-year averted.With market pricing, Rotarix would be associated with a base case cost of $74.73 per disability-adjusted life-year averted. Key variables influencing results were vaccine efficacy, under-2 rotavirus mortality, and program cost of administering each dose. Conclusions. Adopting Rotarix would likely be highly cost-effective for Malawi, particularly with GAVI support. This finding holds true across uncertainty ranges for key variables, including efficacy, for which data are becoming available.

AB - Background. Rotarix (GlaxoSmithKline), a newly licensed rotavirus vaccine requiring 2 doses, may have the potential to save hundreds of thousands of lives in Africa. Nations such as Malawi, where Rotarix is currently under phase III investigation, may nevertheless face difficult economic choices in considering vaccine adoption. Methods. The cost-effectiveness of implementing a Rotarix vaccine program in Malawi was estimated using published estimates of rotavirus burden, vaccine efficacy, and health care utilization and costs. Results. With 49.5% vaccine efficacy, a Rotarix program could avert 2582 deaths annually.With GAVI Alliance cofinancing, adoption of Rotarix would be associated with a cost of $5.07 per disability-adjusted life-year averted.With market pricing, Rotarix would be associated with a base case cost of $74.73 per disability-adjusted life-year averted. Key variables influencing results were vaccine efficacy, under-2 rotavirus mortality, and program cost of administering each dose. Conclusions. Adopting Rotarix would likely be highly cost-effective for Malawi, particularly with GAVI support. This finding holds true across uncertainty ranges for key variables, including efficacy, for which data are becoming available.

UR - http://www.scopus.com/inward/record.url?scp=77955674823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955674823&partnerID=8YFLogxK

U2 - 10.1086/653578

DO - 10.1086/653578

M3 - Article

C2 - 20684689

AN - SCOPUS:77955674823

VL - 202

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - SUPPL. 1

ER -